Literature DB >> 9782309

Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection.

M F Liu1, Q Ning, M Pope, T Mosmann, J Leibowitz, J W Ding, L S Fung, O Rotstein, R Gorczynski, G A Levy.   

Abstract

Murine hepatitis virus strain 3 (MHV-3) produces a host-strain-dependent spectrum of disease. The development of liver necrosis has been shown to be related to production of a unique macrophage procoagulant activity (PCA), encoded by the gene fgl-2, in susceptible mice. These studies were designed to examine the influence of Th1/Th2 cells on resistance/susceptibility and production of macrophage procoagulant activity (PCA) in resistant (A/J) and susceptible (Balb/cJ) strains of mice following infection with MHV-3. Immunization of A/J mice with MHV-3 induced a Th1 cellular immune response and one Th1 cell line (3F9.1) protected susceptible mice and inhibited production of PCA by macrophages both in vitro and in vivo. In contrast, immunization of Balb/cJ mice with an attenuated variant of MHV-3 derived from passaging MHV-3 in YAC-1 cells resulted in a Th2 response. Transfer of spleen cells and T cell lines from immunized Balb/cJ mice failed to protect naive susceptible syngeneic mice from infection with MHV-3 and augmented production of IL-1 beta, TNF-alpha and PCA by macrophages to MHV-3 in vitro. Serum from immunized Balb/cJ mice contained high titered neutralizing antibody which protected naive Balb/cJ animals from lethal primary MHV-3 infection. These results demonstrate that susceptible Balb/cJ mice generate a Th2 response following MHV-3 infection and that these Th2 cells neither inhibit MHV-3-induced macrophage PCA production nor protect naive mice from MHV-3 infection. The results suggest that antibody protects against primary infection, but could not eradicate ongoing infection. Ribavirin, a synthetic guanosine analogue prolonged survival to MHV-3 infection, inhibited production and transcription of the macrophage pro-inflammatory cytokines IL-1 beta and TNF-alpha and Th2 cytokines while preserving Th1 cytokine production. Thus, this data defines the differential role of Th1/Th2 lymphocytes in primary and secondary MHV-3 infection and further defines the importance of macrophage inflammatory mediators in the pathogenesis of MHV-3 infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9782309     DOI: 10.1007/978-1-4615-5331-1_52

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  10 in total

1.  Mechanism of action of ribavirin in the treatment of chronic hepatitis C.

Authors:  Helen S Te; Glenn Randall; Donald M Jensen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

2.  Inhibition of Borna disease virus replication by ribavirin.

Authors:  I Jordan; T Briese; D R Averett; W I Lipkin
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

3.  The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis.

Authors:  Philip A Marsden; Qin Ning; Laisum S Fung; Xioping Luo; Yue Chen; Michael Mendicino; Anand Ghanekar; Jeremy A Scott; Teresa Miller; Camie W Y Chan; Mathew W C Chan; Wei He; Reginald M Gorczynski; David R Grant; David A Clark; M James Phillips; Gary A Levy
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

4.  Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth.

Authors:  Benjamin W Neuman; David A Stein; Andrew D Kroeker; Amy D Paulino; Hong M Moulton; Patrick L Iversen; Michael J Buchmeier
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

5.  Neuroprotection and reduced proliferation of microglia in ribavirin-treated bornavirus-infected rats.

Authors:  Marylou V Solbrig; Robert Schlaberg; Thomas Briese; Nigel Horscroft; W Ian Lipkin
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

6.  Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates.

Authors:  Shih-Jen Liu; Chih-Hsiang Leng; Shu-Pei Lien; Hsiang-Yun Chi; Chiung-Yi Huang; Chang-Ling Lin; Wei-Cheng Lian; Chi-Ju Chen; Shie-Liang Hsieh; Pele Chong
Journal:  Vaccine       Date:  2006-02-08       Impact factor: 3.641

7.  Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity.

Authors:  Gary A Levy; Gord Adamson; M James Phillips; Louise A Scrocchi; Laisum Fung; Pieter Biessels; Nancy F Ng; Anand Ghanekar; Andrea Rowe; Max Xuezhong Ma; Adam Levy; Cheryl Koscik; William He; Reginald Gorczynski; Steve Brookes; Caroline Woods; Ian D McGilvray; David Bell
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425

8.  Synergistic antiviral effect of a combination of mouse interferon-alpha and interferon-gamma on mouse hepatitis virus.

Authors:  Uichiro Fuchizaki; Shuichi Kaneko; Yasunari Nakamoto; Yoshihiro Sugiyama; Kenichi Imagawa; Mikio Kikuchi; Kenichi Kobayashi
Journal:  J Med Virol       Date:  2003-02       Impact factor: 2.327

Review 9.  T cell responses to SARS-CoV-2 in humans and animals.

Authors:  Sameer-Ul-Salam Mattoo; Jinjong Myoung
Journal:  J Microbiol       Date:  2022-02-14       Impact factor: 2.902

Review 10.  How the SARS vaccine effort can learn from HIV-speeding towards the future, learning from the past.

Authors:  Anne S De Groot
Journal:  Vaccine       Date:  2003-10-01       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.